IMMUNOCORE HOLDINGS PLC-ADR (IMCR) Stock Price & Overview
NASDAQ:IMCR • US45258D1054
Current stock price
The current stock price of IMCR is 28.56 USD. Today IMCR is down by -2.53%. In the past month the price decreased by -2.99%. In the past year, price decreased by -6.24%.
IMCR Key Statistics
- Market Cap
- 1.448B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.70
- Dividend Yield
- N/A
IMCR Stock Performance
IMCR Stock Chart
IMCR Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to IMCR. When comparing the yearly performance of all stocks, IMCR is a bad performer in the overall market: 79.66% of all stocks are doing better.
IMCR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMCR. Both the profitability and financial health of IMCR have multiple concerns.
IMCR Earnings
On February 25, 2026 IMCR reported an EPS of -0.6 and a revenue of 104.48M. The company missed EPS expectations (-141.86% surprise) and missed revenue expectations (-4.55% surprise).
IMCR Forecast & Estimates
23 analysts have analysed IMCR and the average price target is 68.07 USD. This implies a price increase of 138.33% is expected in the next year compared to the current price of 28.56.
For the next year, analysts expect an EPS growth of -61.51% and a revenue growth 11.62% for IMCR
IMCR Groups
Sector & Classification
IMCR Financial Highlights
Over the last trailing twelve months IMCR reported a non-GAAP Earnings per Share(EPS) of -0.7. The EPS increased by 31.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -3.33% | ||
| ROE | -9.32% | ||
| Debt/Equity | 1.03 |
IMCR Ownership
IMCR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.31 | 351.47B | ||
| AMGN | AMGEN INC | 14.9 | 185.95B | ||
| GILD | GILEAD SCIENCES INC | 14.45 | 161.855B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.87 | 109.449B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.88 | 79.456B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.2 | 40.768B | ||
| INSM | INSMED INC | N/A | 29.176B | ||
| NTRA | NATERA INC | N/A | 28.878B | ||
| BIIB | BIOGEN INC | 11.21 | 27.06B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.812B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.4 | 24.859B | ||
| MRNA | MODERNA INC | N/A | 20.119B | ||
| INCY | INCYTE CORP | 12.37 | 18.836B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IMCR
Company Profile
Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease. The company is headquartered in Abingdon, Oxfordshire and currently employs 524 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The firm has a pipeline of clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, ovarian, lung, colorectal and others.
Company Info
IPO: 2021-02-05
IMMUNOCORE HOLDINGS PLC-ADR
92 Park Drive Milton Park
Abingdon OXFORDSHIRE OX14 4RY GB
CEO: Bahija Jallal
Employees: 524
Phone: 441235438600
IMMUNOCORE HOLDINGS PLC-ADR / IMCR FAQ
What does IMMUNOCORE HOLDINGS PLC-ADR do?
Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease. The company is headquartered in Abingdon, Oxfordshire and currently employs 524 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The firm has a pipeline of clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, ovarian, lung, colorectal and others.
What is the current price of IMCR stock?
The current stock price of IMCR is 28.56 USD. The price decreased by -2.53% in the last trading session.
What is the dividend status of IMMUNOCORE HOLDINGS PLC-ADR?
IMCR does not pay a dividend.
What is the ChartMill technical and fundamental rating of IMCR stock?
IMCR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of IMCR stock?
IMMUNOCORE HOLDINGS PLC-ADR (IMCR) operates in the Health Care sector and the Biotechnology industry.
Can you provide the ownership details for IMCR stock?
You can find the ownership structure of IMMUNOCORE HOLDINGS PLC-ADR (IMCR) on the Ownership tab.
What is the Short Interest ratio of IMMUNOCORE HOLDINGS PLC-ADR (IMCR) stock?
The outstanding short interest for IMMUNOCORE HOLDINGS PLC-ADR (IMCR) is 20.48% of its float.